Results 251 to 260 of about 504,443 (306)
Inferior Vena Cava-Atrial Anastomosis in Liver Transplant Recipient with Inferior Vena Cava Occlusion: A Case Report and Literature Review. [PDF]
Rochoń J +4 more
europepmc +1 more source
Outcomes of inferior vena cava filtration in lung transplant recipients. [PDF]
Naser-Tavakolian K +7 more
europepmc +1 more source
ABSTRACT Introduction Deferred cytoreductive nephrectomy may improve the prognosis of patients with metastatic renal cell carcinoma (RCC). However, reports of combined hepatic resection for RCC with liver invasion are limited, and treatment strategies remain insufficiently established.
Yuki Hiroshi +8 more
wiley +1 more source
Right heart catheterization via hemiazygos-azygos collaterals in the setting of inferior vena cava stenosis. [PDF]
Shah AK +9 more
europepmc +1 more source
ABSTRACT Introduction Immune checkpoint inhibitors have shown only limited clinical efficacy in germ cell tumors (GCTs), underscoring the need for predictive biomarkers such as microsatellite instability‐high (MSI‐high). We report a rare case of mixed‐type GCTs treated with chemotherapy, in which the somatic‐type malignancy (STM) component was found to
Gaku Hayashi +8 more
wiley +1 more source
Long-standing inferior vena cava filter with multidirectional strut penetration: A case report. [PDF]
Mohamed NSA +5 more
europepmc +1 more source
ABSTRACT Introduction Periureteral IgG4‐related disease (IgG4‐RD) is rare and can mimic upper tract urothelial carcinoma (UTUC), sometimes leading to unnecessary nephroureterectomy. Diagnosis is challenging when endoscopic biopsy is inconclusive and percutaneous biopsy is unsafe.
Takeshi Yoshida +9 more
wiley +1 more source
Double-J stent traversing the inferior vena cava into the right atrium: a rare cause of bacteremia after chronic stent retention. [PDF]
Weerasooriya M +5 more
europepmc +1 more source
ABSTRACT Background Belzutifan, a hypoxia‐inducible factor 2α (HIF‐2α) inhibitor, is effective for metastatic renal cell carcinoma (mRCC), although its cardiovascular safety profile remains unclear. Case Presentation A 52‐year‐old woman with mRCC developed progressive dyspnea and a 6.7‐kg weight gain 27 days after initiating belzutifan as third‐line ...
Hikaru Kimura +9 more
wiley +1 more source

